Navigation Links
Portola Pharmaceuticals Announces Positive Phase II EXPERT Results,and Additional Oral and Poster Presentations at the XXI Congress of,the International Society on Thrombosis and Haemostasis (ISTH)

nticoagulant initially being studied for the prevention of venous thromboembolism in patients who have undergone orthopedic surgery. Portola expects to develop PRT054021 for additional indications including stroke prevention in patients with atrial fibrillation and secondary prevention of myocardial infarction and stroke. Factor Xa is a validated target (one for which there are approved drugs on the market), and inhibiting its activity is believed to have superior anticoagulant properties compared to other targets such as thrombin. Portola believes its oral Factor Xa inhibitor will offer several advantages, including a long half-life to support once daily dosing and a low peak-to-trough concentration ratio, resulting in consistent activity that does not require monitoring or dose adjustment. In addition, PRT054021 is not excreted in the kidneys and therefore will not require dose adjustment in patients with impaired renal function.

About PRT060128 -- Portola's ADP Receptor Antagonist

PRT060128 is an antiplatelet drug that is the only intravenous (IV) and oral ADP receptor antagonist in clinical development. Portola believes that this compound may provide significant clinical benefit through immediate, high-level platelet inhibition in the acute setting and a seamless transition to predictable, reversible platelet inhibition in the chronic setting. Portola has studied this compound in a robust Phase I clinical development program including single ascending dose and multiple ascending dose studies with the oral formulation and a single ascending dose study with the IV formulation. Based on positive results from these studies, Portola intends to initiate its Phase II program in the second half of 2007.

About Portola Pharmaceuticals, Inc.

Portola Pharmaceuticals, Inc. is a privately-held biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapeutics for acute and chronic cardiovascular and vascul
'"/>




Page: 1 2 3

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Portola Pharmaceuticals Announces Positive Phase II Results for PRT054021 for Prevention of Venous Thromboembolism Following Total Knee Replacement Surgery
3. Portola Pharmaceuticals Presents Positive Phase I Data of Its ADP Receptor Antagonist at the American College of Cardiology
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:8/3/2015)... -- Sage Analytics ( www.sageanalytics.com ), the developers of a ... announced its sponsorship of the California Cannabis Industry Association ... of tickets are available for groups or individuals to ... enjoying an open bar, buffet dinner and hors d,oeuvres, ... at sunset. With the legislative session in ...
(Date:8/3/2015)... , August 3, 2015 ... expected to reach USD 24.7 billion by 2022, ... Research Inc. Growing prevalence of neurological and musculoskeletal ... market over the forecast period. The presence of ... cryotherapy, advancement in the technologies coupled with implementation ...
(Date:8/3/2015)... SINGAPORE , Aug. 3, 2015 ... Bloomberg: BIG SP; Reuters: BIOS.SI; SGX: B20), a ... today announced financial results for its first fiscal ... Quarter Highlights and Recent Developments: ... progress in improving its cost structure, driven by ...
Breaking Medicine Technology:Sage Analytics Sponsors California Cannabis Industry Association Bay Area Cruise FUNdraiser 2Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 2Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 3Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 4Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 5Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 2Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 3Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 4Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 5Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 6
... COLLEGEVILLE, Pa., May 30 Wyeth,Pharmaceuticals, a ... today announced the,initiation of the INTORACT (INvestigation ... worldwide randomized, open-label, phase 3b,study comparing TORISEL(R) ... for first-line treatment of patients,with advanced renal ...
... INC. (Nasdaq: VION ) today announced that ... agent Cloretazine(R) (VNP40101M) in,acute myelogenous leukemia (AML) would ... of Clinical Oncology (ASCO(R)) Annual Meeting in Chicago,Illinois., ... blind placebo-controlled,randomized phase III study of high-dose continuous ...
Cached Medicine Technology:Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer 2Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer 3Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer 4Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer 5Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer 6Vion Pharmaceuticals to Present Clinical Data on Cloretazine(R) (VNP40101M) at the ASCO(R) Annual Meeting 2Vion Pharmaceuticals to Present Clinical Data on Cloretazine(R) (VNP40101M) at the ASCO(R) Annual Meeting 3
(Date:8/3/2015)... ... 03, 2015 , ... According to an opinion piece published July 28 by the ... one pound of weight loss may not be accurate. While this system may work for ... of fat varies – based both on the individual and at what point that person ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... diseases researchers from the University of Pittsburgh School of Medicine are leading a ... prevention drugs in sub-Saharan Africa. , A cooperative agreement awarded by the ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... fitness site and the largest online retailer of nutritional supplements, has officially ... is up for 11 awards in the following categories:, ...
(Date:8/3/2015)... TAMPA, Florida (PRWEB) , ... August 03, 2015 ... ... Association for Physician Leadership ® and Navigant Center for Healthcare Research and Policy ... nationwide. , Fifty-five percent of respondents said they agreed or strongly agreed that ...
(Date:8/3/2015)... ... 2015 , ... A July 9 article from USA Today has ... to the American Dental Association. According to a study by the American Dental Association, ... in a single year to 2.2 million a year. Dentists and ADA officials all ...
Breaking Medicine News(10 mins):Health News:Article Dispelling Weight Loss Myth Correctly Emphasizes the Complicated and Difficult Nature of Weight Loss, Says Dr. Michael Feiz 2Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 2Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 4Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 2Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 3Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 3Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 2Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 3
... VEGAS, Oct. 7 Cord Blood America, Inc. (OTC Bulletin ... ( http://www.cordblood-america.com ) focused on bringing the ... to families nationwide and internationally, said today that it has ... the third quarter of 2009. Total debt eliminated in ...
... The Ensign Group, Inc. (Nasdaq: ENSG ), announced ... skilled nursing and independent living campus, as well as ... acquisition was effective October 1, 2009. , (Logo: ... existing operational base and broaden our service offerings in ...
... LONDON and WASHINGTON, Oct. 7 Tranziger Limited announced ... team to advise and assess companies in the life ... realise and optimise value from their portfolios in these ... UK and has offices in Washington, DC and Edinburgh. ...
... ... Flexible Hypervisor Technologies Managed by Unified Set of Automation Tools Enable Profitable Cloud Services ... ... leader, Parallels , today announced enhancements to its server virtualization product portfolio to ...
... ... security landscape, endpoint security, and IT GRC with industry leaders , ... Scottsdale, AZ (PRWEB) October 7, 2009 -- As cybercrime ... organizations are faced with the challenge of staying ahead of these threats. To enable ...
... ... cancer research and support foundation. , ... Hampton Roads, Va. (PRWEB) October 7, 2009--October is breast cancer awareness month. Customer Magnetism, ... of funds from all new contracts signed and received during this month toward breast cancer ...
Cached Medicine News:Health News:Cord Blood America Announces Debt Reduction Tally: $8.7 Million in 2009; $3.7 Million in Third Quarter 2Health News:The Ensign Group Acquires Dallas Skilled Nursing Campus and Hospice Business 2Health News:The Ensign Group Acquires Dallas Skilled Nursing Campus and Hospice Business 3Health News:Tranziger Announces Formation of Global Advisory & Development Team 2Health News:Tranziger Announces Formation of Global Advisory & Development Team 3Health News:Parallels Server Bare Metal Launches, Building on Parallels' Containers Leadership to Enable Cloud Services Providers to Extend Virtualized Services 2Health News:Parallels Server Bare Metal Launches, Building on Parallels' Containers Leadership to Enable Cloud Services Providers to Extend Virtualized Services 3Health News:Parallels Server Bare Metal Launches, Building on Parallels' Containers Leadership to Enable Cloud Services Providers to Extend Virtualized Services 4Health News:Parallels Server Bare Metal Launches, Building on Parallels' Containers Leadership to Enable Cloud Services Providers to Extend Virtualized Services 5Health News:Lumension Launches New Optimal IT Security Videocast Series 2Health News:Lumension Launches New Optimal IT Security Videocast Series 3Health News:Customer Magnetism Donates Funds In Support Of Breast Cancer Research 2Health News:Customer Magnetism Donates Funds In Support Of Breast Cancer Research 3
... Direct has been selling replacement ... 1996, and we are extremely ... guarantee. Check out our catalog ... our discount light bulbs specials. ...
... Direct has been selling replacement ... 1996, and we are extremely ... guarantee. Check out our catalog ... our discount light bulbs specials. ...
... Bulb Direct has been selling ... since 1996, and we are ... satisfaction guarantee. Check out our ... see our discount light bulbs ...
... Direct has been selling replacement ... 1996, and we are extremely ... guarantee. Check out our catalog ... our discount light bulbs specials. ...
Medicine Products: